RT Journal Article
SR Electronic
T1 Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.05.21264567
DO 10.1101/2021.10.05.21264567
A1 Dunkle, Lisa M.
A1 Kotloff, Karen L.
A1 Gay, Cynthia L.
A1 Áñez, Germán
A1 Adelglass, Jeffrey M.
A1 Barrat Hernández, Alejandro Q.
A1 Harper, Wayne L.
A1 Duncanson, Daniel M.
A1 McArthur, Monica A.
A1 Florescu, Diana F.
A1 McClelland, R. Scott
A1 Garcia-Fragoso, Veronica
A1 Riesenberg, Robert A.
A1 Musante, David B.
A1 Fried, David L.
A1 Safirstein, Beth E.
A1 McKenzie, Mark
A1 Jeanfreau, Robert J.
A1 Kingsley, Jeffrey K.
A1 Henderson, Jeffrey A.
A1 Lane, Dakotah C.
A1 Ruíz-Palacios, Guillermo M.
A1 Corey, Lawrence
A1 Neuzil, Kathleen M.
A1 Coombs, Robert W.
A1 Greninger, Alex L.
A1 Hutter, Julia
A1 Ake, Julie A.
A1 Smith, Katherine
A1 Woo, Wayne
A1 Cho, Iksung
A1 Glenn, Gregory M.
A1 Dubovsky, Filip
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/10/10/2021.10.05.21264567.abstract
AB BACKGROUND Vaccination using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein antigen has been effective in the prevention of coronavirus disease 2019 (Covid-19). NVX-CoV2373 is an adjuvanted, recombinant S protein nanoparticle vaccine that demonstrated clinical efficacy for prevention of Covid-19 in phase 2b/3 trials in the United Kingdom and South Africa.METHODS This phase 3, randomized, observer-blinded, placebo-controlled trial evaluated the efficacy and safety of NVX-CoV2373 in adults ≥18 years of age in the United States and Mexico during the first quarter of 2021. Participants were randomized in a 2:1 ratio to receive two doses of NVX-CoV2373 or placebo 21 days apart. The primary end point was vaccine efficacy (VE) against reverse transcriptase-polymerase chain reaction-confirmed Covid-19 in SARS-CoV-2-naïve participants ≥7 days after the second dose administration.RESULTS Of the 29,949 participants randomized between December 27, 2020, and February 18, 2021, 29,582 (median age: 47 years, 12.6% ≥65 years) received ≥1 dose: 19,714 received vaccine and 9868 placebo. In the per-protocol population, there were 77 Covid-19 cases; 14 among vaccine and 63 among placebo recipients (VE: 90.4%, 95% confidence interval [CI] 82.9 to 94.6, P<0.001). All moderate-to-severe cases occurred in placebo recipients, yielding VE of 100% (95% CI 87.0 to 100). Most sequenced viral genomes (48/61, 78.7%) were variants of concern (VOC) or interest (VOI), mainly represented by variant alpha/B.1.1.7 (31/35, 88.6% VOC identified). VE against any VOC/VOI was 92.6% (95% CI 83.6 to 96.7). Reactogenicity was mostly mild-to-moderate and transient, but more frequent in NVX-CoV2373 recipients and after the second dose. Serious adverse events were rare and evenly distributed between treatments.CONCLUSIONS NVX-CoV2373 was well tolerated and demonstrated a high overall VE (>90%) for prevention of Covid-19, with most cases due to variant strains.(Funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; PREVENT-19 ClinicalTrials.gov number, NCT04611802.)Competing Interest StatementDisclosure forms provided by the authors will be available with the full text of this article upon publication.Clinical TrialNCT04611802Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04611802?cond=NCT04611802&draw=2&rank=1 Funding StatementFunded by Novavax, by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following Institutional Review Boards / Independent Ethics committees reviewed and approved the study: -Western Copernicus Group IRB, US; Great Plains IRB, US; Comite de etica en investigacion del Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico; Comite de etica en investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C., Mexico; Comite de etica en investigacion del Instituto Nacional de Salud Publica, Mexico; Comite de etica en investigacion de Medica Rio Mayo S.C., Mexico; Comite de etica en investigacion del Hospital La Mision S.A. de C.V., Mexico All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Sharing Statement will be available with the full text of this article upon publication. https://clinicaltrials.gov/ct2/show/NCT04611802?cond=NCT04611802&draw=2&rank=1